RP1
vusolimogene odeparepvec
engineered HSV backbone, GM-CSF, GALV-GP R-
Trial
IGNYTE
Phase 1
Phase 2
Phase 3
Commercial
- IGNYTE trial of RP1 + nivolumab in advanced melanoma has completed enrollment with a PDUFA date of July 22, 2025.
- Clinical trial collaboration and supply agreement with BMS for the supply of nivolumab – full commercial rights retained by Replimune.
Trial
IGNYTE-3
Phase 1
Phase 2
Phase 3
Commercial
- IGNYTE‑3 confirmatory trial in advanced melanoma underway and currently enrolling.
merkel cell carcinoma, basal cell carcinoma, angiosarcoma
Trial
IGNYTE
Phase 1
Phase 2
Phase 3
Commercial
- IGNYTE trial cohort evaluating RP1 + nivolumab in non-melanoma skin cancers including anti-PD1-failed.
- Clinical trial collaboration and supply agreement with BMS for the supply of nivolumab – full commercial rights retained by Replimune.
Trial
ARTACUS
Phase 1
Phase 2
Phase 3
Commercial
- The ARTACUS trial is evaluating RP1 as monotherapy in patients with skin cancer who have received an organ transplant.